Britannia Life Sciences Inc (TSE:BLAB)
:BLAB
BLAB Stock Chart & Stats
C$0.08
C$0.00(0.00%)
At close: 4:00 PM EST
C$0.08
C$0.00(0.00%)
Day’s Range― - ―
52-Week RangeC$0.05 - C$0.14
Previous CloseN/A
Volume35.00K
Average Volume (3M)73.07K
Market Cap
C$14.60M
Enterprise ValueC$13.03M
Total Cash (Recent Filing)C$15.89M
Total Debt (Recent Filing)C$248.56K
Price to Earnings (P/E)0.3
Beta-1.30
Next Earnings
Aug 04, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.07
Shares Outstanding162,254,330
10 Day Avg. Volume81,691
30 Day Avg. Volume73,070
Financial Highlights & Ratios
PEG Ratio-0.81
Price to Book (P/B)1.93
Price to Sales (P/S)32.95
P/FCF Ratio-4.65
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
End-to-end Service ModelOffering end-to-end product development, testing, regulatory and analytics services builds durable client relationships and higher switching costs. Long project lifecycles and regulatory complexity favor recurring contracts and cross-selling, supporting sustained revenue visibility and client stickiness.
Diversified Industry ExposureServing multiple end markets (health, beauty, food) reduces concentration and cyclicality risk and enables revenue synergies across adjacent sectors. Diverse client demand and ability to repurpose capabilities support steadier long-term demand and growth opportunities across product categories.
Meaningfully Improved Balance SheetVery low leverage and a stronger capital base materially lower solvency and refinancing risk, giving the company flexibility to fund operations, absorb cash burn, or invest in strategic initiatives without immediate pressure from creditors, improving long-term resilience.
Bears Say
Material Negative Cash FlowSustained negative operating and free cash flow increases funding risk and can force reliance on external financing or equity raises. That reduces financial flexibility, can dilute stakeholders, and constrains reinvestment in R&D, sales, or capacity that are needed for durable growth.
Volatile Revenue And Earnings QualityLarge swings in revenue and inconsistent operating profits undermine predictability and the ability to scale margins. Volatility hampers planning, weakens operating leverage benefits, and suggests the company may not yet have stable product-market fits or pricing power.
Stronger Capital Not Yet Driving ProfitabilityDespite a healthier balance sheet, the company has failed to convert capital strength into sustained returns. This indicates potential structural issues in execution, pricing, or cost control that must be resolved before the firm achieves self-sustaining profitability and long-term value creation.
Britannia Life Sciences Inc News
BLAB FAQ
What was Britannia Life Sciences Inc’s price range in the past 12 months?
Britannia Life Sciences Inc lowest stock price was C$0.05 and its highest was C$0.14 in the past 12 months.
What is Britannia Life Sciences Inc’s market cap?
Britannia Life Sciences Inc’s market cap is C$14.60M.
When is Britannia Life Sciences Inc’s upcoming earnings report date?
Britannia Life Sciences Inc’s upcoming earnings report date is Aug 04, 2026 which is in 122 days.
How were Britannia Life Sciences Inc’s earnings last quarter?
Britannia Life Sciences Inc released its earnings results on Mar 02, 2026. The company reported C$0.075 earnings per share for the quarter, beating the consensus estimate of N/A by C$0.075.
Is Britannia Life Sciences Inc overvalued?
According to Wall Street analysts Britannia Life Sciences Inc’s price is currently Overvalued.
Does Britannia Life Sciences Inc pay dividends?
Britannia Life Sciences Inc does not currently pay dividends.
What is Britannia Life Sciences Inc’s EPS estimate?
Britannia Life Sciences Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Britannia Life Sciences Inc have?
Britannia Life Sciences Inc has 162,254,330 shares outstanding.
What happened to Britannia Life Sciences Inc’s price movement after its last earnings report?
Britannia Life Sciences Inc reported an EPS of C$0.075 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Britannia Life Sciences Inc?
Currently, no hedge funds are holding shares in TSE:BLAB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Britannia Life Sciences Inc
Britannia Life Sciences Inc. provides product testing, safety assessment, and compliance services to the cosmetics, nutraceutical, and consumer packaged goods industries in the United Kingdom and internationally. The company is based in Toronto, Canada.
Technical Analysis
Hemostemix
―
Innovotech
―
Sirona Biochem
―
Glow LifeTech
―
Telescope Innovations Corp
―